Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Luspatercept

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    BMS' Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial
    BMS' Anemia Drug Reblozyl Flunks Phase III Myelofibrosis Trial

    19 Jul 2025

    // BIOSPACE

    https://www.biospace.com/drug-development/bms-anemia-drug-reblozyl-flunks-phase-iii-myelofibrosis-trial

    BIOSPACE
    19 Jul 2025
    Share Share
    Celgene Corp's Reblozyl® (luspatercept-aamt) Receives Suppl Approval in US
    Celgene Corp's Reblozyl® (luspatercept-aamt) Receives Suppl Approval in US

    16 May 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761136

    FDA
    16 May 2024
    Share Share
    Ahead of likely approval, ICER finds Geron’s imetelstat at $250,000 annually
    Ahead of likely approval, ICER finds Geron’s imetelstat at $250,000 annually

    09 May 2024

    // Lia DeGroot ENDPTS

    https://endpts.com/ahead-of-likely-approval-icer-finds-gerons-imetelstat-is-not-cost-effective-at-250000-annually/

    Lia DeGroot ENDPTS
    09 May 2024
    Share Share
    EC Expands Approval of BMS Reblozyl for LR-MDS
    EC Expands Approval of BMS Reblozyl for LR-MDS

    02 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240402231542/en

    BUSINESSWIRE
    02 Apr 2024
    Share Share
    EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes
    EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

    02 Apr 2024

    // INDIANPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/ec-expands-reblozyls-approval-for-treatment-of-myelodysplastic-syndromes-15475

    INDIANPHARMAPOST
    02 Apr 2024
    Share Share
    Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl
    Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl

    23 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240221131768/en

    BUSINESSWIRE
    23 Feb 2024
    Share Share